Vertex presented the Phase 3 clinical data of the Vanza Triple and new data on the long-term impact of TRIKAFTA at the North American Cystic Fibrosis Conference.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor…

Read More: https://www.businesswire.com/news/home/20240925704457/en/